Autoimmune pancreatitis: pathogenesis, latest developments and clinical guidance

Area of Science:

• Immunology
• Gastroenterology
• Pathology

Background:

• Autoimmune pancreatitis (AIP) is now classified into two subtypes: Type 1, associated with immunoglobulin G4 (IgG4), and Type 2, characterized by granulocytic epithelial lesions.
• Pathogenetic mechanisms for both AIP subtypes remain incompletely understood.
• Type 1 AIP exhibits features like elevated serum IgG4/IgE, IgG4+ plasmacyte infiltration, fibrosis, and steroid responsiveness, suggesting immune dysregulation.

Purpose of the Study:

• To review recent advances in the pathogenesis of autoimmune pancreatitis subtypes.
• To discuss clinical guidance for the therapeutic management of autoimmune pancreatitis.
• To highlight differences in relapse rates and post-remission strategies between Type 1 and Type 2 AIP.

Main Methods:

• Literature review of recent advances in autoimmune pancreatitis research.
• Analysis of clinical data regarding therapeutic responses and relapse rates.
• Discussion of current clinical guidance for steroid maintenance and relapse management.

Main Results:

• Both Type 1 and Type 2 AIP demonstrate good initial response to steroid therapy.
• Type 1 AIP shows significantly higher relapse rates (30-50% within 6-12 months) compared to Type 2 AIP.
• Therapeutic strategies for relapsing Type 1 AIP vary among different clinical centers.

Conclusions:

• Despite distinct pathophysiological features, both AIP subtypes are steroid-responsive.
• The high relapse rate in Type 1 AIP necessitates individualized post-remission management and ongoing research into pathogenesis.
• Further clarification of AIP pathogenesis is crucial for optimizing long-term patient outcomes.